Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene LabBGLC +3.33%56 Days Payable is 7.24 as of Jun. 2026, which is 90% below its 10-year median of 71.82. GuruFocus rates BGLC with a GF Score™ of 56/100 and a GF Value™ of $1.25 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,563 Chemicals companies, BioNexus Gene Lab ranks worse than 67.56% on this metric.
The historical rank and industry rank for BioNexus Gene Lab's Days Payable or its related term are showing as below:
BGLC'
s Days Payable Range Over the Past 10 Years
Min: 41.68 Med: 71.82 Max: 119.69
Current: 41.68
During the past 8 years, BioNexus Gene Lab's highest Days Payable was 119.69. The lowest was 41.68. And the median was 71.82.
BGLC's Days Payable is ranked worse than 67.56% of 1563
companies
in the Chemicals industry
Industry Median: 59.22
vs BGLC: 41.68
BioNexus Gene Lab's Days Payable
declined
from Jun. 2025 (61.52) to Jun. 2026 (7.24).
It may suggest that BioNexus Gene Labaccelerated paying its suppliers.
The historical data trend for BioNexus Gene Lab's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Days Payable vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Days Payable distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BioNexus Gene Lab's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a Days Payable of 7.24 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioNexus Gene Lab and its competitors. This is 90% below median its historical median of 71.82. Over the past decade, BioNexus Gene Lab's Days Payable has ranged from 41.68 to 119.69. According to the industry distribution chart, BioNexus Gene Lab ranks #1056 out of 1563 companies in the Chemicals industry, placing it in the top 67.6%.
Is BioNexus Gene Lab's Days Payable too high?
BioNexus Gene Lab's current Days Payable of 7.24 is 90% below median its 10-year median of 71.82. Over the past 10 years, this metric has ranged from a low of 41.68 to a high of 119.69. The Chemicals industry median Days Payable is 59.22. BioNexus Gene Lab's value of 7.24 is 87.8% below this industry median. Based on the distribution chart, BioNexus Gene Lab ranks #1056 out of 1563 companies in the Chemicals industry, which is below the industry midpoint. Overall, BioNexus Gene Lab has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Days Payable compare to VYST and QGAI?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #1056 out of 1563 companies for Days Payable. This places BioNexus Gene Lab in the lower half of its industry. The industry median Days Payable is 59.22. BioNexus Gene Lab's value of 7.24 is 87.8% below this benchmark. Historically, BioNexus Gene Lab's own Days Payable has ranged from 41.68 to 119.69 over the past decade. While the company's 10-year median is 71.82 vs. the industry median of 59.22, BioNexus Gene Lab has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Chemicals company?
The median Days Payable among Chemicals companies is 59.22, based on 1,563 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNexus Gene Lab's current Days Payable of 7.24 is 87.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioNexus Gene Lab and its competitors. For the Chemicals industry, the median Days Payable is 59.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current Days Payable is 7.24, which is 90% below median its own 10-year median of 71.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $1.55 — trading 24% above its estimated fair value. The current Days Payable is 7.24, which is 90% below median its 10-year median of 71.82 and 87.8% below the Chemicals industry median of 59.22. BioNexus Gene Lab's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Days Payable is 7.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be overvalued.
The current stock price of $1.55 is trading 24% above its estimated GF Value™ of $1.25.
GuruFocus considers BioNexus Gene Lab to be Modestly Overvalued.
Key valuation signals for BGLC:
Days Payable: 7.24 (90% below median its 10-year median of 71.82)
GF Value™: $1.25 vs. price of $1.55 (24% above fair value)
Industry Position: 87.8% below the Chemicals median (#1056 of 1563)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
56GF Score
Get the complete analysis for BGLC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
